Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on INVESTMENT MANAGERS SER TR II stock.
TAO Synergies Inc., formerly Synaptogenix, reports developments tied to its Nasdaq-listed common stock, corporate rebranding, and digital asset treasury strategy centered on TAO, the native cryptocurrency of the Bittensor network. Recurring updates include TAO acquisitions, staking activity, custody and trading arrangements, ticker-symbol changes, shareholder voting matters, governance actions, and capital-structure disclosures.
The company’s historical Synaptogenix news also covers clinical-stage biopharmaceutical work in neurodegenerative disorders through Bryostatin-1 and polyunsaturated fatty acid analogs, including FDA-authorized IND activity, orphan-drug designation for Fragile X syndrome, patent matters, and research collaborations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Synaptogenix, Inc. (SNPX) reported promising secondary endpoint results from an NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients. The company has approximately $37.5 million in cash as of December 31, 2022, maintaining a robust financial position. The Phase 2 trial results showed statistical significance in secondary endpoints for the most severe Alzheimer's patient population (MMSE-2 scores of 10-14), indicating potential efficacy. Synaptogenix aims to explore acquisition opportunities and continue collaborations with strategic partners to enhance shareholder value.
Synaptogenix, Inc. (Nasdaq: SNPX) announced topline results from its NIH-sponsored Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease. The trial failed to meet its primary endpoint, showing an average increase in the Severe Impairment Battery (SIB) score of only 1.4 points for the treatment group compared to 0.6 points for the placebo group at week 28. CEO Alan Tuchman expressed disappointment and indicated a review of the trial data to determine next steps. The company remains well-capitalized, holding approximately $38.5 million in cash as of December 15, 2022.